| Patritumab Deruxtecan studied in …STUDIED_INderived20 of 20show fewer |
|---|
| → studied in | NCT07060807Phase 3 · recruiting A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016) · 20 trials list this drug (14 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07286149Phase 1/Phase 2 · recruiting A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F) · 20 trials list this drug (14 active) | — | — | Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06941272Phase 1/Phase 2 · recruiting A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01) · 20 trials list this drug (14 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06797635Phase 2 · recruiting Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03) · 20 trials list this drug (14 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06298084Phase 1/Phase 2 · recruiting Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd · 20 trials list this drug (14 active) | — | — | Malignant Breast Neoplasm,HER2-Low Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06469944Phase 1/Phase 2 · recruiting Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06) · 20 trials list this drug (14 active) | — | — | Esophageal Neoplasm,Malignant Esophageal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04619004Phase 2 · active not recruiting HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer · 20 trials list this drug (14 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06596694Phase 1/Phase 2 · recruiting Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02) · 20 trials list this drug (14 active) | — | — | Malignant Digestive System Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05338970Phase 3 · active not recruiting HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy · 20 trials list this drug (14 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07701941Phase 1/Phase 2 · not yet recruiting A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer · 20 trials list this drug (14 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04699630Phase 2 · completed A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer · 20 trials list this drug (14 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06686394Phase 1/Phase 2 · recruiting Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009) · 20 trials list this drug (14 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05865990Phase 2 · completed HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease · 20 trials list this drug (14 active) | — | — | Adult Solid Neoplasm,Malignant Breast Neoplasm,Lung Non-Small Cell Squamous Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04965766Phase 2 · recruiting Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer · 20 trials list this drug (14 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06383884Phase 2 · recruiting Patritumab Deruxtecan in Patients With Solid Tumor Harboring an NRG1 Fusion · 20 trials list this drug (14 active) | — | — | Adult Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05620914Phase 2 · withdrawn A Window of Opportunity Study of Patritumab Deruxtecan in Patients With Brain Metastases · 20 trials list this drug (14 active) | — | — | Brain Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04479436Phase 2 · terminated A Study to Evaluate U3-1402 in Subjects With Advanced or Metastatic Colorectal Cancer · 20 trials list this drug (14 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02980341Phase 1/Phase 2 · completed Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer · 20 trials list this drug (14 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05569811Phase 2 · active not recruiting NeoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer - VALENTINE Trial · 20 trials list this drug (14 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04610528early Phase 1 · unknown A Window-of-opportunity Study of U3-1402, a HER3-targeting Antibody-drug Conjugate in Operable Breast Cancer According to ERBB3 Expression · 20 trials list this drug (14 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |